BACKGROUND: Recent evidence suggests that de novo donor-specific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and graft failure after kidney transplantation. The effects of induction immunosuppression on dnDSA are unknown. METHODS: The study population comprised 114 consecutive moderately sensitized (positive DSA and negative flow crossmatch) recipients who received deceased donor renal transplants between December 2009 and November 2011. Patients were divided into two groups based on induction immunosuppression: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29) and were followed up for 36 months. RESULTS: Patients in the ATG group received a mean dose of 4.98 mg/kg ± 7.9 mg/kg, had a significantly higher PRA, and received more plasmapheresis and IVIG at the time of transplant. The incidence of dnDSA (P=0.02, HR=0.33, 95% CI 0.09-1.24) and ABMR (P=0.002, HR=0.2, 95% CI 0.04-0.87) was significantly lower in the ATG group. In multivariate regression analyses, ATG induction was the single most important variable associated with both ABMR and dnDSA. CONCLUSIONS: In moderately sensitized deceased donor renal transplant recipients, induction with ATG is associated with a reduction in the occurrence of dnDSA and ABMR when compared with basiliximab.
BACKGROUND: Recent evidence suggests that de novo donor-specific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and graft failure after kidney transplantation. The effects of induction immunosuppression on dnDSA are unknown. METHODS: The study population comprised 114 consecutive moderately sensitized (positive DSA and negative flow crossmatch) recipients who received deceased donor renal transplants between December 2009 and November 2011. Patients were divided into two groups based on induction immunosuppression: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29) and were followed up for 36 months. RESULTS:Patients in the ATG group received a mean dose of 4.98 mg/kg ± 7.9 mg/kg, had a significantly higher PRA, and received more plasmapheresis and IVIG at the time of transplant. The incidence of dnDSA (P=0.02, HR=0.33, 95% CI 0.09-1.24) and ABMR (P=0.002, HR=0.2, 95% CI 0.04-0.87) was significantly lower in the ATG group. In multivariate regression analyses, ATG induction was the single most important variable associated with both ABMR and dnDSA. CONCLUSIONS: In moderately sensitized deceased donor renal transplant recipients, induction with ATG is associated with a reduction in the occurrence of dnDSA and ABMR when compared with basiliximab.
Authors: S Gurkan; Y Luan; N Dhillon; S R Allam; T Montague; J S Bromberg; S Ames; S Lerner; Z Ebcioglu; V Nair; R Dinavahi; V Sehgal; P Heeger; B Schroppel; B Murphy Journal: Am J Transplant Date: 2010-09 Impact factor: 8.086
Authors: James E Cooper; Jane Gralla; Linda Cagle; Ryan Goldberg; Laurence Chan; Alexander C Wiseman Journal: Transplantation Date: 2011-05-27 Impact factor: 4.939
Authors: Martin S Zand; Thuong Vo; Jennifer Huggins; Raymond Felgar; Jane Liesveld; Tina Pellegrin; Adel Bozorgzadeh; Ignacio Sanz; Benjamin J Briggs Journal: Transplantation Date: 2005-06-15 Impact factor: 4.939
Authors: B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi Journal: Am J Transplant Date: 2010-01-29 Impact factor: 8.086
Authors: C Lefaucheur; C Suberbielle-Boissel; G S Hill; D Nochy; J Andrade; C Antoine; C Gautreau; D Charron; D Glotz Journal: Am J Transplant Date: 2007-12-19 Impact factor: 8.086
Authors: L G Hidalgo; P M Campbell; B Sis; G Einecke; M Mengel; J Chang; J Sellares; J Reeve; P F Halloran Journal: Am J Transplant Date: 2009-11 Impact factor: 8.086
Authors: Judith E Worthington; Susan Martin; Dalia M Al-Husseini; Philip A Dyer; Robert W G Johnson Journal: Transplantation Date: 2003-04-15 Impact factor: 4.939
Authors: Christian Noël; Daniel Abramowicz; Dominique Durand; Georges Mourad; Philippe Lang; Michèle Kessler; Bernard Charpentier; Guy Touchard; François Berthoux; Pierre Merville; Nacera Ouali; Jean-Paul Squifflet; François Bayle; Karl Martin Wissing; Marc Hazzan Journal: J Am Soc Nephrol Date: 2009-05-21 Impact factor: 10.121
Authors: Meghan H Pearl; Qiuheng Zhang; Miguel Fernando Palma Diaz; Jonathan Grotts; Maura Rossetti; David Elashoff; David W Gjertson; Patricia Weng; Elaine F Reed; Eileen Tsai Chambers Journal: Kidney Int Date: 2017-09-18 Impact factor: 10.612
Authors: Natalie M Bath; Arjang Djamali; Sandesh Parajuli; Didier Mandelbrot; Glen Leverson; Luis Hidalgo; Thomas Ellis; Jillian L Descourouez; Margaret R Jorgenson; Dave Hager; Dixon B Kaufman; Robert R Redfield Journal: Kidney360 Date: 2020-10-01
Authors: Brian C Eby; Robert R Redfield; Thomas M Ellis; Glen E Leverson; Abby R Schenian; Jon S Odorico Journal: Transplantation Date: 2016-05 Impact factor: 4.939
Authors: C K Burghuber; J Kwun; E J Page; M Manook; A C Gibby; F V Leopardi; M Song; A B Farris; J J Hong; F Villinger; A B Adams; N N Iwakoshi; S J Knechtle Journal: Am J Transplant Date: 2016-03-25 Impact factor: 8.086